Literature DB >> 25747660

Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.

Tarik Asselah1.   

Abstract

Entities:  

Keywords:  Asunaprevir; Daclatasvir; Egypt; Ledipasvir; Ombitasvir; Paritaprevir; Simeprevir; Sofosbuvir

Mesh：

Substances：

Year:  2015        PMID： 25747660     DOI： 10.1016/j.jhep.2015.03.003

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  1 in total

1.  Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).

Authors:  Tarik Asselah; Negar Niki Alami; Christophe Moreno; Stanislas Pol; Stylianos Karatapanis; Michael Gschwantler; Yves Horsmans; Ioannis Elefsiniotis; Dominique Larrey; Carlo Ferrari; Mario Rizzetto; Alessandra Orlandini; Jose Luis Calleja; Savino Bruno; Gretja Schnell; Roula Qaqish; Rebecca Redman; Tami Pilot-Matias; Sarah Kopecky-Bromberg; Yao Yu; Niloufar Mobashery
Journal:  Health Sci Rep       Date:  2019-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.